Extended Data Fig. 8: TREM1 expression in development of AD.
a Immunofluorescent staining of human frontal cortex without addition of TREM1 antibody and secondary only control (red), Iba1 (green), and X-34 (blue) signal. This antibody validation experiment was performed three times. Scale bar = 20 μm. b Immunoblot of TREM1 protein in postmortem human mid frontal gyrus. Clinicopathological diagnoses: non-demented Braak I-II, demented non-AD Braak stages I-II, AD Braak III-IV and AD Braak V-VI. Primary antibody detected human TREM1 band at the molecular weight of positive control (human liver lysates, Cat# HT-314, Zyagen, San Diego, CA). The TREM1 band used for analysis are indicated by blue box. Also shown is the band for ß-actin at 42 kDa. This antibody validation experiment was performed once. c Immunoblot of TREM2 protein in postmortem human mid frontal gyrus. Primary antibody detects human TREM2 band at the molecular weight of positive control (human liver lysates, Cat# HT-314, Zyagen, San Diego, CA). TREM2 bands used for analysis are indicated by blue box. Also shown is the band for ß-actin at 42 kDa. This antibody validation experiment was performed once. d Mendelian Randomization (MR) analyses with Alzheimer’s disease (AD) risk level as exposure and sTREM1 and sTREM2 plasma protein level as outcomes. Blue lines are estimated MR-median weight effects, and the dashed lines indicate the 95% confidence interval for the MR effects.
